What is HC Wainwright’s Forecast for ATXS Q1 Earnings?

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Astria Therapeutics in a research report issued on Tuesday, March 11th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.50) for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.02) EPS and FY2026 earnings at ($1.87) EPS.

Other research analysts have also issued research reports about the stock. JMP Securities initiated coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday. Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Finally, Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Astria Therapeutics has a consensus rating of “Buy” and a consensus target price of $26.67.

Astria Therapeutics Price Performance

Shares of ATXS stock opened at $6.64 on Friday. The firm has a market cap of $374.72 million, a PE ratio of -3.18 and a beta of 0.69. The company has a 50-day moving average of $7.23 and a two-hundred day moving average of $9.59. Astria Therapeutics has a 1-year low of $5.73 and a 1-year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $41,000. Tower Research Capital LLC TRC raised its holdings in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 2,766 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $50,000. Virtus ETF Advisers LLC acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $65,000. Finally, Teacher Retirement System of Texas acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $91,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.